drug · small molecule
givinostat hydrochloride
Marketedupdated 3mo agoby Italfarmaco SpA🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for duchenne muscular dystrophy and 1 investigational indication.
indications
investigational
Duchenne Muscular Dystrophy
targets
Histone deacetylase
all catalysts(0)
nothing on the calendar yet
Trials studying givinostat hydrochloride
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 15, 2027
157 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Oct 28, 2036formulationUS 10688047
- Feb 3, 2032method-of-use (U-3885)US 9421184
- Feb 3, 2032method-of-use (U-3885)US 9867799
- Jan 15, 2027compositionUS 7329689157d
FDA exclusivities (2)
- Mar 21, 2031ODE-473Orphan Drug (7y)4.6y
- Mar 21, 2029NCENew Chemical Entity (5y)2.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that